SPOTLIGHT: Biotech dealmaking poised to explode


Ready for a wave of big biotech acquisitions and mergers? That, and other industry-transforming events, are likely to happen for biotech in the near term, according to consulting firm Ernst & Young. Not only that, but given the hunger for experimental therapies from innovative biotech companies, valuations are likely to run high, keeping the industry insulated from the overall downturn in the U.S. economy. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.